BSW
EIGR

Buckingham Strategic Wealth’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Buckingham Strategic Wealth’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-400
Closed -$8.46K – 724
2023
Q2 		$8.46K Buy
+400
New +$12.3K ﹤0.01% 695

Other funds holding EIGR

Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
RC
RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Buckingham Strategic Wealth's EIGR Position: Q3 2023 in Review

Buckingham Strategic Wealth sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q3 2023, closing a stake of 400 shares — an estimated $8.46K sold.

Buckingham Strategic Wealth first reported a position in EIGR in Q2 2023 and held it in 1 quarter. The position peaked at $8.46K in Q2 2023. 51 funds tracked by Wall St. Rank hold EIGR as of Q3 2023.

  • Buckingham Strategic Wealth reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
  • Buckingham Strategic Wealth sold 400 Eiger BioPharmaceuticals, Inc. shares in Q3 2023, an estimated $8.46K.
  • Buckingham Strategic Wealth first reported a position in Eiger BioPharmaceuticals, Inc. in Q2 2023 and held it in 1 quarter.
  • Buckingham Strategic Wealth's Eiger BioPharmaceuticals, Inc. position peaked at $8.46K in Q2 2023.
  • 51 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q3 2023.

Based on Buckingham Strategic Wealth's 13F filing for Q3 2023, filed 13 Nov 2023.